CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
1.010
-0.050 (-4.72%)
At close: Jun 5, 2025, 4:00 PM
1.020
+0.010 (0.99%)
After-hours: Jun 5, 2025, 4:19 PM EDT
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors.
The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies.
It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | John Climaco |
Contact Details
Address: 2100 West Loop South, Suite 900 Houston, Texas 77027 United States | |
| Phone | 800-946-9185 |
| Website | cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H409 |
| ISIN Number | US18978H4092 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President and Director |
| Christopher S. Downs CPA, CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | 424B4 | Prospectus |
| May 13, 2025 | EFFECT | Notice of Effectiveness |
| May 12, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | DRS | [Cover] Draft Registration Statement |
| Mar 31, 2025 | 8-K | Current Report |